Genomes and Genes
Affiliation: University of Navarra
- Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patientsR Zárate Romero
Laboratory of Biotechnology and Pharmacogenomics, Center for Applied Medical Research, University Clinic of Navarra, Navarra 31008, Spain
Oncol Rep 16:497-503. 2006..Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen...
- Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapyR N Zárate
Laboratory of Biotechnology and Pharmacogenomics, University Clinic of Navarra, Pamplona 31008, Spain
World J Gastroenterol 12:6032-6. 2006..To evaluate the potential association of xeroderma pigmentosum group D (XPD) codon 751 variant with outcome after chemo-radiotherapy in patients with resected gastric cancer...
- GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatmentR Zarate
Laboratory of Biotechnology, University Clinic of Navarra, Pamplona, Spain
Curr Drug Metab 8:481-6. 2007..3 to 254), P = 0.008. Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline-based treatment of breast cancer...
- Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysisR Zarate
Laboratory of Pharmacogenomics, Division of Oncology, CIMA, University Clinic of Navarra, Avda Pio XII 36, Pamplona, Spain
Br J Cancer 102:987-94. 2010..A pharmacogenomic analysis was performed to investigate the association between SNPs and treatment outcome...
- A new mutation in the hMSH2 gene in a Spanish Lynch syndrome familyRuth Zarate
Clinical Genetics Unit, University Clinic of Navarra, Pamplona, Navarra, Spain
Clin Transl Oncol 12:849-51. 2010..The mutation was not present in 116 normal controls screened. The medical implications for the carrier relatives are discussed...
- Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patientsA Abajo
Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
Br J Cancer 103:1529-35. 2010..Pharmacogenomic analysis was performed to investigate the association between VEGF single-nucleotide polymorphisms and clinical outcome...
- Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapyJ Rodriguez
Department of Oncology, Clinic University of Navarra, Pamplona, Spain
Eur J Cancer 47:839-47. 2011..To investigate whether single nucleotide polymorphisms (SNPs) in gemcitabine (GMB) metabolism genes were associated with clinical outcome in pre-treated metastatic colorectal cancer (mCRC) patients...
- Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patientsA Abajo
Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
Br J Cancer 107:287-90. 2012..To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients...
- Combining chemotherapy and targeted therapies in metastatic colorectal cancerJ Rodriguez
Unit for the Research and Treatment of Gastrointestinal Malignancies, Department of Oncology, Clinica Universitaria, Center for Applied Medical Research, University of Navarra, Spain
World J Gastroenterol 13:5867-76. 2007..In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer...
- Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissuesE Bandres
Laboratory of Pharmacogenomics, Cancer Research Program Center for Applied Medical Research, University of Navarra, Navarra, Spain
Mol Cancer 5:29. 2006..In addition, the expression level of miR-31 was correlated with the stage of CRC tumor. Our results suggest that miRNA expression profile could have relevance to the biological and clinical behavior of colorectal neoplasia...
- Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesionsN Ramirez
Laboratory of Pharmacogenomics, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
Eur J Cancer 44:2689-95. 2008..Our results indicate that epigenetic changes in mucosa surrounding colorectal neoplastic lesions may describe a 'field cancerisation' phenomenon that may occur previous to genetic alterations in early stages of carcinogenesis...